Formulary and Prescribing Guidelines
Medicines Management
Please click on the heading to view formulary, shared care guidelines and pathways for each BNF chapter.
Coronavirus (COVID-19) - Patients
COVID 19 AstraZeneca vaccination guide
Patient information - how to help your pharmacy
Frequently asked questions - ordering medicines when self isolating
How patients can order repeat prescriptions electronically
Problems with Sharing of Medicines
Frequently asked questions - Inhalers and Coronavirus
FAQ for patients on immunosuppressants
Palliative care patient information leaflet
Rheumatology advice letter - shielding, self-isolation or maintaining social distancing
Coronavirus (COVID-19) - Clinicians
Vitamin D in Care Homes
Guidance for Care Homes on the use of Vitamin D supplements obtained by the DHSC
Coronavirus Position Statement
Position statement for prescribing for patients abroad during Coronavirus outbreak
Prescription management during COVID-19
Useful Covid-19 Resources
Information around medicines use in Covid-19 is changing rapidly. Stay on top of the most recent information produced by the government and the Royal Pharmaceutical Society, using the links below:
https://www.rpharms.com/coronavirus
https://www.nice.org.uk/covid-19
https://www.gov.uk/government/collections/mhra-guidance-on-coronavirus-covid-19
Please note that only registered users can download the below documents:
Covid-19 Vaccine
COVID-19 primary care vaccine handling and management policy
Covid-19 Vaccine Pharmacy Communications Reference Guide
Letter from Chief Medical Officers re UK Covid-19 Vaccination Programme
Optimising the Covid-19 vaccination programme for maximum short term impact
Patient Group Direction for COVID-19 Vaccines
Standard operating procedure: COVID-19 local vaccination services deployment in community settings
Pfizer
Specialist Pharmacy Service (SPS) Covid-19 Pfizer-BioNTech vaccine resources
Patient Group Direction for COVID 19 mRNA vaccine BNT162b2 (Pfizer BioNTech)
National protocol for COVID-19 mRNA vaccine BNT162b2 (Pfizer/BioNTech)
Referrals for cohort 6 16 and 17 year olds who require a Pfizer vaccination
AstraZeneca
Specialist Pharmacy Service (SPS) - Resources for AstraZeneca Covid-19 vaccine
Patient Group Direction for COVID-19 Vaccine AstraZeneca
National protocol for COVID-19 Vaccine AstraZeneca
Position Statement AstraZeneca Vaccine Movement
Transporting AstraZeneca COVID-19 Vaccine from PCN Designated Sites to end user locations SOP
Moderna
Moderna Covid 19 Vaccine Protocol
Covid-19 and professional advice
Security advice for pharmacies during COVID 19
COVID related professional advice
NHS Volunteer Responders information for health professionals
Covid-19 and services
Remote Outpatient Clinics - Medicines Supply
Responsibility for Prescribing - May 2020
Monitoring of shared care medicines during the COVID 19 pandemic
Access to Palliative Care Drugs for clinicans
Access to EOL Drugs in Primary Care during Covid-19
MSE Hospitals Group Anticoagulation Clinics
Covid-19 and medicines
Ibuprofen and coronavirus (COVID 19)
Rescue packs for COPD and asthma for clinicians
Ramadan summary fasting recommendations - British Islamic Medical Association
Chapter 01 - Gastro-Intestinal System
Budesonide orodispersible for eosinophilic oesophagitis (NICE TA708) position statement
Infliximab (Remsima®) subcutaneous injection for treating Crohn's disease and ulcerative colitis
Electrolyte mix (St Mark's solution)
Fibrates for the management of Primary Biliary Cholangitis (PBC)
Pathway for the management of chronic constipation in adults
Proton pump inhibitor (PPI) use in paediatric patients – prescribing guidance for primary, community and secondary care
Prucalopride for chronic constipation in men
Naldemedine for treating opioid-induced constipation (NICE TA651) MSEMOC position statement
St Mark’s Solution Instructions wards
Sucralfate MSEMOC position statement
Vedolizumab (Entyvio®) subcutaneous injection for treating Crohn's disease and ulcerative colitis
Chapter 02 - Cardiovascular System
Joint cardiovascular System Formulary (MSEMOC)
Atrial fibrillation anticoagulant clinical decision aid
Bempedoic acid with ezetimibe for lipid management (NICE TA694) position statement
Dapagliflozin for treating chronic HF with reduced ejection fraction (NICE TA679) position statement
Doxazosin MR MSEMOC Position statement
Heart failure diuretic flow chart
Heart failure treatment algorithm
Perindopril arginine MSEMOC Position statement
Omega 3 FAs MSEMOC Position statement
Vernakalant for rapid conversion AF to sinus rhythm (NICE TA675) position statement
Chapter 03 - Respiratory System
Chapter 04 - Central Nervous System
Cannabis products MSEMOC position statement
Cenobamate for treating focal onset seizures (NICE TA753) position statement
Chronic Fatigue Syndrome MSEMOC Position statement
Chronic migraine - pathway for PbR excluded drugs for preventing chronic migraine in adults
Co-proxamol MSEMOC position statement
EPUT formulary and shared care guidelines
Erenumab for preventing migraine (NICE TA682) position statement
Fentanyl immediate release preparations MSEMOC position statement
Galcanezumab for preventing migraine (NICE TA659) MSEMOC position statement
Good practice for Paracetamol prescribing
Lidocaine plasters MSEMOC position statement
Low dose naltrexone MSEMOC position statement
Melatonin (Slenyto®) for the treatment of insomnia
Melatonin for children and adolescents
Oxycodone naloxone MSEMOC position statement
Solriamfetol for treating excessive daytime sleepiness (NICE TA758) position statement
Chapter 05 - Infection
Chapter 06 - Endocrine System
Blood glucose testing guidelines, including lancets and insulin pen needles
Dapagliflozin 5mg for Type 1 DIABETES MELLITUS position statement
Dulaglutide for type 2 diabetes mellitus
INTERIM FreeStyle Libre 2 guidance
Gliptin Therapy Data Collection Template
Insulin aspart (Fiasp®) for diabetes mellitus
Insulin glargine 300 units ml (Toujeo)
Liothyronine MSEMOC position statement
Liraglutide for managing overweight and obesity (NICE TA664) MSEMOC position statement
Naltrexone and bupropion MSEMOC position statement
Type 2 diabetes mellitus treatment pathway in adults
Chapter 07 - Genito-Urinary formulary
Chapter 08 - Malignant Disease
Chapter 09 - Nutrition and Blood
Oral Nutritional Supplements Guidelines
Adult Oral Nutritional Supplements Prescribing Guidelines
Quick reference guide to ONS prescribing in adults
Supporting Leaflets for Cows' Milk Allergy
COLOUR Cows' Milk Allergy leaflet for families
BLACK + WHITE Cows' Milk Allergy leaflet for families
Dairy free diet information for breastfeeding mothers
Primary Care Milk Allergy Pathway
Secondary Care Milk Allergy Pathway
Infant Formula Guidelines (IFG)
Infant formula prescribing guidelines
Quick reference guide to prescribing infant formula
Vitamin and Mineral Guidelines
Ferric maltol (Feraccru®) for the treatment of iron deficiency in adults
Probiotics MSEMOC position statement
Vitamins and minerals MSEMOC position statement
Vitamin D deficiency prescribing guidance
Vitamin D for supplementation insufficiency and maintenance doses MSEMOC position statement
Vitamin D - guidance for care homes on the use of Vitamin D supplements obtained by the DHSC
Stopping low dose vitamin D patient letter
Multivitamins post-bariatric surgery MSEMOC position statement
Multivitamins not supported unless for actual vitamin/mineral deficiency
Vitamin B compound MSEMOC Position statement
Gluten-free Prescription Guidelines
Gluten-free foods on prescription
Thickeners for Adults with Dysphagia
A guide to prescribing thickeners for adults
Position Statements
Andexanet alfa for reversing anticoagulation (NICE TA697) position statement
Fostamatinib for treating refractory chronic ITP (NICE TA759) position statement
Sodium zirconium for treating hyperkalaemia (NICE TA599) position statement
Chapter 10 - Musculoskeletal System
Anti TNFs and abatacept for moderate rheumatoid arthritis(NICE TA715) MSEMOC position statement
Ixekizumab for axial spondyloarthritis (NICE TA718) MSEMOC position statement
Filgotinib for treating moderate to severe rheumatoid arthritis (NICE TA676) position statement
Glucosamine MSEMOC Position statement
Guselkumab for psoriatic arthritis (NICE TA711) position statement
Hyaluronic acid MSEMOC position statement
Mexiletine (Namuscla) for treatment of myotonia
Rubefacients MSEMOC Position statement
Secukinumab for non radiographic axial spondyloarthritis (NICE TA719) position statement
Severe psoriatic arthritis treatment pathway
Sodium hyaluronate for osteoarthritis
Upadacitinib for treating moderate rheumatoid arthritis (NICE TA744) position statement
Chapter 11 - Eye
Chapter 12 - Ear, Nose and Oropharynx
Chapter 13 - Skin
Baricitinib for treating moderate to severe atopic dermatitis (NICE TA681) position statement
Bimekizumab for plaque psoriasis (NICE TA723) position statement
Brimonidine tartrate MSEMOC position statement
Camouflage creams MSEMOC position statement
Crisaborole for atopic dermatitis (NICE TA701) position statement
Eflornithine (Vaniqa®) cream MSEMOC position statement
Emollients prescribing guidance
Emollients for dry skin patient letter
Emollients switch to an alternative patient letter
Fungal nail infections topical treatments MSEMOC position statement
Potassium hydroxide 5% (Molludab, Mollutrex) solution MSEMOC position statement
Pigmanorm cream for the treatment of melasma
Severe plaque psoriasis treatment pathway
Sunscreen preparations MSEMOC position statement
Stopping bath and shower emollients patient letter
Chapter 14 – Immunological Products and Vaccines
General Prescribing Guidance
End of Life Formulary
Woundcare Formulary
Traffic Light List for Prescribing
Shared Care Guidelines
Mid and South Essex Medicines Optimisation Committee (MSEMOC)
Prescribing Incentive Scheme
Prescribing Updates / Newsletters
Patient Information
Over the Counter medicines leaflets
Over the counter patient info sheet
Easy read over the counter leaflet
Changes to Co-Proxamol Prescribing
Changes to Dosulepin Prescribing
Changes to Doxazosin Prescribing
Changes to Glucosamine Prescribing
Changes to Herbal Treatment Prescribing
Changes to Homeopathy Prescribing
Changes to Immediate Release Fentanyl Prescribing
Changes to Lidocaine Plaster Prescribing
Changes to liothyronine prescribing
Changes to Lutein and Antioxidant supplements Prescribing
Changes to Omega 3 Fatty Acids Prescribing
Changes to Once Daily Tadalafil Prescribing
Changes to Perindopril Arginine Prescribing
Changes to Rubefacients Prescribing
Changes to Targinact Prescribing
Changes to Tramacet Prescribing
Changes to Travel Vaccines Prescribing
Changes to Trimipramine Prescribing
Patient Letters
Practice Resources/Policies
Electronic Prescription Service (EPS)
Electronic Repeat Dispensing (eRD)
Guide for Designated Medical Practitioners
Instructions for Requests for Prescribing Code or Changes to practices
Management and control of prescription forms
Mid and South Essex Proxy Ordering User Guide GP Surgeries and Care Homes
Reauthorisation of B12 Injections
What products or interventions are available to aid medication adherence
Eclipse
National Medicine Shortages
Please note that only registered users can download the below documents:
February 2022